Polyclonal Antibody to Inositol-1,4,5-Trisphosphate Receptor Type 2 (ITPR2)
| Code | Size | Price |
|---|
| PAE844Hu01-20ul | 20ul | £95.00 |
Quantity:
| PAE844Hu01-100ul | 100ul | £180.00 |
Quantity:
| PAE844Hu01-200ul | 200ul | £245.00 |
Quantity:
| PAE844Hu01-1ml | 1ml | £566.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
IP3R2; IP3 receptor isoform 2; Type 2 inositol 1,4,5-trisphosphate receptor; Type 2 InsP3 receptor
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Immunogen:
RPE844Hu01-Recombinant Inositol-1,4,5-Trisphosphate Receptor Type 2 (ITPR2)
Item Name:
Inositol-1,4,5-Trisphosphate Receptor Type 2
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Subcategory:
Polyclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Inositol-1,4,5-Trisphosphate Receptor Type 2 (ITPR2) | RPE844Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||